

glofitamab (Columvi)

SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2614	as monotherapy for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	10/06/2024	31/08/2024
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/media/8388/glofitamab-columvi-final-may-2024-amended-050624-for-website.pdf				

voxelotor (Oxbryta)

SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2626	treatment of haemolytic anaemia due to sickle cell disease (SCD) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide. SMC restriction: as a second line treatment for haemolytic anaemia in patients with SCD who are intolerant, ineligible or have an inadequate response to, hydroxycarbamide.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	10/06/2024	31/08/2024
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/media/8386/voxelotor-oxbryta-final-may-2024-for-website.pdf				

epcoritamab (Tepkinly)				
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2632	as monotherapy for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	10/06/2024	31/08/2024
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/media/8387/epcoritamab-tepkinly-final-may-2024-amended-050624-for-website.pdf				
momelotinib (Omjjara)				
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2636	Treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis and who are Janus Associated Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	10/06/2024	31/08/2024
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/media/8384/momelotonib-omjjara-abb-final-may-2024-for-website.pdf				

tirzepatide (Mounjaro)				
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2653	<p>For weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial Body Mass Index (BMI) of ≥ 30 kg/m² (obesity) or ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).</p> <p>SMC restriction: for use in adults with BMI ≥ 30 kg/m²* and at least one weight-related comorbidity. *a lower BMI cut-off may be more appropriate for members of minority ethnic groups known to be at equivalent risk of the consequences of obesity at a lower BMI than the white population.</p>	Not routinely available as the ADTC is waiting for further advice from local clinical experts	10/06/2024	31/08/2024
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/media/8389/tirzepatide-mounjaro-final-may-2024-amended-050624-for-website.pdf				

etrasimod (Velsipity®)				
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2655	for the treatment of patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	10/06/2024	31/08/2024
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/media/8383/etrasimod-film-coated-tablets-velsipity-abb-final-may-2024-for-website.pdf				
clostridium botulinum neurotoxin type A (Xeomin®)				
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2680	focal spasticity of the lower limb affecting the ankle joint.	Not routinely available as not recommended for use in NHS Scotland	10/06/2024	19/06/2024
Other Decision Specified : Non-submission				
Web Link : https://www.scottishmedicines.org.uk/media/8380/clostridium-botulinum-neurotoxin-type-a-xeomin-non-sub-final-may-2024-for-website.pdf				

decitabine cedazuridine (Inaqovi)				
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2681	as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for standard induction chemotherapy.	Not routinely available as not recommended for use in NHS Scotland	10/06/2024	19/06/2024
Other Decision Specified : Non-submission				
Web Link : https://www.scottishmedicines.org.uk/media/8381/decitabine-cedazuridine-inaqovi-non-sub-final-may-2024-for-website.pdf				
dupilumab (Dupixent®)				
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2682	treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.	Not routinely available as not recommended for use in NHS Scotland	10/06/2024	19/06/2024
Other Decision Specified : Non-submission				
Web Link : https://www.scottishmedicines.org.uk/media/8382/dupilumab-dupixent-non-sub-final-may-2024-for-website.pdf				

pembrolizumab (Keytruda)				
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2683	in combination with gemcitabine and cisplatin for the first-line treatment of locally advanced unresectable or metastatic biliary tract carcinoma in adults.	Not routinely available as not recommended for use in NHS Scotland	10/06/2024	19/06/2024
Other Decision Specified : Non-submission				
Web Link : https://www.scottishmedicines.org.uk/media/8385/pembrolizumab-keytruda-non-sub-final-may-2024-for-website.pdf				